StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Repligen's market cap was $9.74B on Nov 11, 2026, against $9.63B a year earlier. Over the last 5 years it ranged from $6.58B to $14.64B, with a median of $9.12B.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$9.74B+5.6%
2025Dec 31, 2025$9.22B+14.4%
2024Dec 31, 2024$8.06B-19.6%
2023Dec 29, 2023$10.03B+6.7%
2022Dec 30, 2022$9.40B-35.8%
2021Dec 31, 2021$14.64B+45.2%
2020Dec 31, 2020$10.08B+109.4%
2019Dec 31, 2019$4.81B+108.2%
2018Dec 31, 2018$2.31B+46.4%
2017Dec 29, 2017$1.58B+51.6%
2016Dec 30, 2016$1.04B+11.9%
2015Dec 31, 2015$931.97M+43.9%
2014Dec 31, 2014$647.52M+48.9%
2013Dec 31, 2013$434.88M+124.7%
2012Dec 31, 2012$193.50M+81.0%
2011Dec 30, 2011$106.92M-25.9%
2010Dec 31, 2010$144.23M–

More Repligen figures

See a number that looks wrong?